journal
MENU ▼
Read by QxMD icon Read
search

Oncologist

journal
https://www.readbyqxmd.com/read/27903924/randomized-phase-ii-study-of-cabazitaxel-versus-methotrexate-in-patients-with-recurrent-and-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-previously-treated-with-platinum-based-therapy
#1
Jean-Pascal Henry Machiels, Aline Van Maanen, Jean-Marie Vandenbulcke, Bertrand Filleul, Emmanuel Seront, Stéphanie Henry, Lionel D'Hondt, Christophe Lonchay, Stéphane Holbrechts, Petra Boegner, Dany Brohee, Didier Dequanter, Ingrid Louviaux, Brieuc Sautois, Nicolas Whenham, Guy Berchem, Brigitte Vanderschueren, Christel Fontaine, Sandra Schmitz, Aline Gillain, Joelle Schoonjans, Sylvie Rottey
LESSONS LEARNED: Cabazitaxel has activity in squamous cell carcinoma of the head and neck (SCCHN) and taxane-resistant cell lines. For the first time, cabazitaxel was investigated in incurable patients with recurrent SCCHN. Patients were randomly assigned to cabazitaxel every 3 weeks or weekly methotrexate.This phase II study did not meet its primary endpoint.Cabazitaxel has low activity in SCCHN.The toxicity profile in this population also was not favorable owing to the high rate of febrile neutropenia observed (17%)...
November 30, 2016: Oncologist
https://www.readbyqxmd.com/read/27881709/relationship-between-metformin-use-and-recurrence-and-survival-in-patients-with-resected-stage-iii-colon-cancer-receiving-adjuvant-chemotherapy-results-from-north-central-cancer-treatment-group-n0147-alliance
#2
Preet Paul Singh, Qian Shi, Nathan R Foster, Axel Grothey, Suresh G Nair, Emily Chan, Anthony F Shields, Richard M Goldberg, Sharlene Gill, Morton S Kahlenberg, Frank A Sinicrope, Daniel J Sargent, Steven R Alberts
BACKGROUND: Preclinical and epidemiological data suggest that metformin might have antineoplastic properties against colon cancer (CC). However, the effect of metformin use on patient survival in stage III CC after curative resection is unknown. The survival outcomes were comparable regardless of the duration of metformin use. PATIENTS AND METHODS: Before randomization to FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin) with or without cetuximab, 1,958 patients with stage III CC enrolled in the N0147 study completed a questionnaire with information on diabetes mellitus (DM) and metformin use...
November 23, 2016: Oncologist
https://www.readbyqxmd.com/read/27864576/a-case-of-nivolumab-induced-myositis
#3
LETTER
Eric Fox, Michael Dabrow, Greg Ochsner
No abstract text is available yet for this article.
November 18, 2016: Oncologist
https://www.readbyqxmd.com/read/27864575/tumor-humor
#4
Benjamin W Corn
No abstract text is available yet for this article.
November 18, 2016: Oncologist
https://www.readbyqxmd.com/read/27864574/enhancing-endocrine-therapy-combination-strategies-for-the-treatment-of-postmenopausal-hormone-receptor-positive-her2-advanced-breast-cancer
#5
REVIEW
Kathleen I Pritchard, Stephen K Chia, Christine Simmons, Deanna McLeod, Alexander Paterson, Louise Provencher, Daniel Rayson
: : Breast cancer (BC) is the most common malignancy in women worldwide, with approximately two-thirds having hormone receptor (HR)-positive tumors. New endocrine therapy (ET) strategies include combining ET agents as well as adding inhibitors targeting growth factors, angiogenesis, the mechanistic target of rapamycin, phosphoinositide 3-kinase (PI3K), or cyclin-dependent kinase 4/6 to ET. Level 1 evidence supports use of fulvestrant plus anastrozole or palbociclib plus letrozole as first-line therapy for HR-positive, HER2-negative advanced BC with special consideration for the former in ET-naïve patients, as well as everolimus plus exemestane or palbociclib plus fulvestrant as second-line therapy with special consideration in select first-line patients...
November 18, 2016: Oncologist
https://www.readbyqxmd.com/read/27821795/the-elimination-of-cancer-health-disparities-are-we-ready-to-do-the-heavy-lifting
#6
Jonathan D Jackson, Beverly Moy, Michele K Evans
No abstract text is available yet for this article.
November 7, 2016: Oncologist
https://www.readbyqxmd.com/read/27821794/understanding-mechanisms-of-resistance-in-the-epithelial-growth-factor-receptor-in-non-small-cell-lung-cancer-and-the-role-of-biopsy-at-progression
#7
REVIEW
Mark A Socinski, Liza C Villaruz, Jeffrey Ross
: : Molecular profiling and the discovery of drugs that target specific activating mutations have allowed the personalization of treatment for non-small cell lung cancer (NSCLC). The epithelial growth factor receptor (EGFR) is frequently overexpressed and/or aberrantly activated in different cancers, including NSCLC. The most common activating mutations of EGFR in NSCLC fall within the tyrosine kinase-binding domain. Three oral EGFR tyrosine kinase inhibitors (TKIs) have been approved by the U...
November 7, 2016: Oncologist
https://www.readbyqxmd.com/read/27821793/a-study-of-thymidylate-synthase-expression-as-a-biomarker-for-resectable-colon-cancer-alliance-cancer-and-leukemia-group-b-9581-and-89803
#8
Donna Niedzwiecki, Rian M Hasson, Heinz-Josef Lenz, Cynthia Ye, Mark Redston, Shuji Ogino, Charles S Fuchs, Carolyn C Compton, Robert J Mayer, Richard M Goldberg, Thomas A Colacchio, Leonard B Saltz, Robert S Warren, Monica M Bertagnolli
PURPOSE: Tumor levels of thymidylate synthase (TS), a target of 5-fluorouracil (5-FU)-based chemotherapy for colorectal cancer, have been studied as a predictive or prognostic biomarker with mixed results. PATIENTS AND METHODS: Tumor TS levels were prospectively evaluated in two adjuvant therapy trials for patients with resected stage II or III colon cancer. TS expression was determined by standard immunohistochemistry and by automated quantitative analysis. Tumor mismatch repair deficiency (MMR-D) and BRAF c...
November 7, 2016: Oncologist
https://www.readbyqxmd.com/read/27807304/hent-1-expression-and-localization-predict-outcome-after-adjuvant-gemcitabine-in-resected-cholangiocarcinoma-patients
#9
LETTER
Laura L Meijer, Jisce R Puik, Godefridus J Peters, Geert Kazemier, Elisa Giovannetti
No abstract text is available yet for this article.
November 2, 2016: Oncologist
https://www.readbyqxmd.com/read/27807303/targeting-the-kras-pathway-in-non-small-cell-lung-cancer
#10
REVIEW
Pascale Tomasini, Preet Walia, Catherine Labbe, Kevin Jao, Natasha B Leighl
: : Lung cancer remains the leading cause of cancer-related deaths worldwide. However, significant progress has been made individualizing therapy based on molecular aberrations (e.g., EGFR, ALK) and pathologic subtype. KRAS is one of the most frequently mutated genes in non-small cell lung cancer (NSCLC), found in approximately 30% of lung adenocarcinomas, and is thus an appealing target for new therapies. Although no targeted therapy has yet been approved for the treatment of KRAS-mutant NSCLC, there are multiple potential therapeutic approaches...
November 2, 2016: Oncologist
https://www.readbyqxmd.com/read/27807302/sunitinib-ten-years-of-successful-clinical-use-and-study-in-advanced-renal-cell-carcinoma
#11
REVIEW
Robert J Motzer, Bernard Escudier, Andrew Gannon, Robert A Figlin
: : The oral multikinase inhibitor sunitinib malate was approved by the U.S. Food and Drug Administration in January 2006 for use in patients with advanced renal cell carcinoma (RCC). Since then, it has been approved globally for this indication and for patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors and advanced pancreatic neuroendocrine tumors. As we mark the 10-year anniversary of the beginning of the era of targeted therapy, and specifically the approval of sunitinib, it is worthwhile to highlight the progress that has been made in advanced RCC as it relates to the study of sunitinib...
November 2, 2016: Oncologist
https://www.readbyqxmd.com/read/27807301/in-reply
#12
LETTER
Giovanni Brandi, Marzia Deserti, Francesco Vasuri, Andrea Farioli, Alessio Degiovanni, Andrea Palloni, Giorgio Frega, Maria A Barbera, Stefania de Lorenzo, Ingrid Garajova, Mariacristina Di Marco, Antonio D Pinna, Matteo Cescon, Alessandro Cucchetti, Giorgio Ercolani, Antonietta D'Errico-Grigioni, Maria A Pantaleo, Guido Biasco, Simona Tavolari
No abstract text is available yet for this article.
November 2, 2016: Oncologist
https://www.readbyqxmd.com/read/27807300/bridging-the-gap-between-sorafinib-efficacy-and-effectiveness-in-advanced-hepatocellular-carcinoma
#13
Ryan Nipp, Lipika Goyal
No abstract text is available yet for this article.
November 2, 2016: Oncologist
https://www.readbyqxmd.com/read/27789778/a-phase-i-study-of-the-safety-and-pharmacokinetics-of-higher-dose-icotinib-in-patients-with-advanced-non-small-cell-lung-cancer
#14
Jian Liu, Lihua Wu, Guolan Wu, Xingjiang Hu, Huili Zhou, Junchun Chen, Meixiang Zhu, Wei Xu, Fenlai Tan, Lieming Ding, Yinxiang Wang, Jianzhong Shentu
LESSONS LEARNED: This phase I study evaluated the maximum tolerated dose, dose-limiting toxicities, safety, pharmacokinetics, and efficacy of icotinib with a starting dose of 250 mg in pretreated, advanced non-small cell lung cancer patients. We observed a maximum tolerated dose of 500 mg with a favorable pharmacokinetics profile and antitumor activity.These findings provide clinicians with evidence for application of higher-dose icotinib. BACKGROUND: Icotinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has shown favorable tolerability and antitumor activity at 100-200 mg in previous studies without reaching the maximum tolerated dose (MTD)...
October 27, 2016: Oncologist
https://www.readbyqxmd.com/read/27789777/does-a-higher-cutoff-value-of-lymph-node-retrieval-substantially-improve-survival-in-patients-with-advanced-gastric-cancer-time-to-embrace-a-new-digit
#15
Yu-Yin Liu, Wen-Liang Fang, Frank Wang, Jun-Te Hsu, Chun-Yi Tsai, Keng-Hao Liu, Chun-Nan Yeh, Tse-Ching Chen, Ren-Chin Wu, Cheng-Tang Chiu, Ta-Sen Yeh
BACKGROUND: The present study assessed the impact of the retrieval of >25 lymph nodes (LNs) on the survival outcome of patients with advanced gastric cancer after curative-intent gastrectomy. PATIENTS AND METHODS: A total of 5,386 patients who had undergone curative gastrectomy for gastric cancer from 1994 to 2011 were enrolled. The clinicopathological parameters and overall survival (OS) were analyzed according to the number of LNs examined (≤15, n = 916; 16-25, n = 1,458; and >25, n = 3,012)...
October 27, 2016: Oncologist
https://www.readbyqxmd.com/read/27789776/chemotherapy-near-the-end-of-life-for-chinese-patients-with-solid-malignancies
#16
Jin Sheng, Ya-Xiong Zhang, Xiao-Bo He, Wen-Feng Fang, Yun-Peng Yang, Gui-Nan Lin, Xuan Wu, Ning Li, Jing Zhang, Lin-Zhu Zhai, Yuan-Yuan Zhao, Yan Huang, Ning-Ning Zhou, Hong-Yun Zhao, Li Zhang
INTRODUCTION: There are increasing concerns about the negative impacts of chemotherapy near the end of life (EOL). There is discrepancy among different countries about its use, and little is known about the real-world situation in China. PATIENTS AND METHODS: This retrospective study was conducted at six representative hospitals across China. Adult decedents with a record of advanced solid cancer and palliative chemotherapy were consecutively screened from 2010 through 2014...
October 27, 2016: Oncologist
https://www.readbyqxmd.com/read/27789775/phase-ii-and-biomarker-study-of-cabozantinib-in-metastatic-triple-negative-breast-cancer-patients
#17
Sara M Tolaney, David R Ziehr, Hao Guo, Mei R Ng, William T Barry, Michaela J Higgins, Steven J Isakoff, Jane E Brock, Elena V Ivanova, Cloud P Paweletz, Michelle K Demeo, Nikhil H Ramaiya, Beth A Overmoyer, Rakesh K Jain, Eric P Winer, Dan G Duda
: : There are currently no targeted therapies available for metastatic triple-negative breast cancer (mTNBC). We evaluated the safety, efficacy, and biomarkers of response to cabozantinib, a multikinase inhibitor, in patients with mTNBC. We conducted a single-arm phase 2 and biomarker study that enrolled patients with measurable mTNBC. Patients received cabozantinib (60mg daily) on a 3-week cycle, and were restaged after 6 weeks and then every 9 weeks. The primary endpoint was objective response rate...
October 27, 2016: Oncologist
https://www.readbyqxmd.com/read/27742908/phase-ii-trial-of-abiraterone-acetate-plus-prednisone-in-black-men-with-metastatic-prostate-cancer
#18
Che-Kai Tsao, John Sfakianos, Bobby Liaw, Kiev Gimpel-Tetra, Margaret Kemeny, Linda Bulone, Mohammad Shahin, William Kyu Oh, Matthew David Galsky
LESSONS LEARNED: The safety and activity findings of abiraterone acetate plus prednisone treatment in black men with mCRPC were similar to results from previously conducted studies with largely white populations.Poor trial accrual continues to be a challenge in black men with mCRPC and further efforts are needed to address such underrepresentation. BACKGROUND: Self-identified black men have higher incidence and mortality from prostate cancer in the United States compared with white men but are dramatically underrepresented in clinical trials exploring novel therapies for metastatic castration-resistant prostate cancer (mCRPC)...
October 14, 2016: Oncologist
https://www.readbyqxmd.com/read/27742907/the-impact-of-an-educational-program-on-patient-practices-for-safe-use-storage-and-disposal-of-opioids-at-a-comprehensive-cancer-center
#19
Maxine de la Cruz, Akhila Reddy, Vishidha Balankari, Margeaux Epner, Susan Frisbee-Hume, Jimin Wu, Diane Liu, Sriram Yennurajalingam, Hilda Cantu, Janet Williams, Eduardo Bruera
BACKGROUND: Improper use, storage, and disposal of prescribed opioids can lead to diversion or accidental poisoning. Our previous study showed a large proportion of cancer patients have unsafe opioid practices. Our objective was to determine whether an improvement occurred in the patterns of use, storage, and disposal of opioids among cancer outpatients after the implementation of a patient educational program. PATIENTS AND METHODS: Our palliative care (PC) clinic provides every patient with educational material (EM) on safe opioid use, storage, and disposal every time they receive an opioid prescription...
October 14, 2016: Oncologist
https://www.readbyqxmd.com/read/27742906/eribulin-in-male-patients-with-breast-cancer-the-first-report-of-clinical-outcomes
#20
Francesco Giotta, Luigi Acito, Giampiero Candeloro, Pietro Del Medico, Gennaro Gadaleta-Caldarola, Guido Giordano, Rossana Gueli, Antonio Lugini, Valentina Magri, Marta Mandarà, Giovanna Masci, Salvatore Pisconti, Mirco Pistelli, Anna Rizzi, Nello Salesi, Alessio Schirone, Giovanni Scognamiglio, Maria Tedeschi, Patrizia Zucchinelli
BACKGROUND: Evidence on the management and treatment of male breast cancer is scant. We report the analysis of a multicenter Italian series of patients with male breast cancer treated with eribulin. To our knowledge, this is the first report on the use or eribulin in this setting. PATIENTS AND METHODS: Patients were retrospectively identified in 19 reference centers. All patients received eribulin treatment, according to the standard practice of each center. Data on the identified patients were collected using a standardized form and were then centrally reviewed by two experienced oncologists...
October 14, 2016: Oncologist
journal
journal
20207
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"